IL-6 decreased | IL-6 stable | IL-6 increased | All patients | |
No of patients (%) | 11 (23) | 21 (44) | 15 (32) | 47 |
Interval between pretreatment and mid-treatment plasma draw in days, median (range) | 28 (17–196) | 22 (20–126) | 28 (21–70) | 28 (17–196) |
Age at treatment start, median (range) | 63 (46–62) | 73 (50–89) | 72 (52–80) | 66 (46–89) |
Male sex, n (%) | 6 (54) | 5 (24) | 5 (33) | 16 (34) |
Performance status 0/1/2 | 3/8/0 | 4/14/3 | 3/11/1 | 10/33/4 |
Smoking history, n (%) | 10 (91) | 20 (95) | 14 (93) | 44 (94) |
Histology, n (%) | ||||
Adenocarcinoma | 10 (91) | 18 (86) | 11 (73) | 39 (83) |
Squamous | 1 (9) | 3 (14) | 4 (27) | 8 (17) |
KRAS mutated/assessed (%) | 0/11 (0) | 7/19 (37) | 5/14 (43) | 12/44 (27) |
TMB, median mut/MB (range) | 15 (8–27) | 8 (4–42) | 5 (2–18) | 8 (2–42) |
Patients with data not available (%) | 4 (36) | 10 (48) | 6 (40) | 20 (42) |
PD-L1 percentage, median (range) | 85 (30–95) | 50 (0–95) | 70 (5–80) | 70 (0–95) |
Patients with data not available (%) | 5 (45) | 7 (33) | 6 (40) | 18 (38) |
Treatment type | ||||
Pembrolizumab | 6 (54) | 15 (71) | 12 (80) | 33 (70) |
Nivolumab | 4 (36) | 5 (24) | 1 (7) | 10 (21) |
Atezolizumab | 1 (9) | 0 | 2 (13) | 3 (6) |
Durvalumab | 0 | 1 (5) | 0 | 1 (2) |
Line of therapy, median (range) | 2 (1–6) | 1 (1–5) | 1 (1–3) | 1 (1–6) |
PFS in months, median (range) | 11 (4–44) | 5 (1–33) | 4 (1–24) | 4 (1–44) |
Patients without progression at 12 months/patients with either progression or at least 12 months of follow-up (%) | 5/11 (45) | 4/19 (21) | 2/14 (14) | 11/44 (25) |
IL-6, interleukin 6; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; PFS, progression-free survival; TMB, tumor mutation burden.